Gene Therapy in Spinal Muscular Atrophy (SMA)

Introduction And Genetic Basis

Spinal Muscular Atrophy (SMA) is a severe, progressive autosomal recessive neuromuscular disorder caused by homozygous deletions or mutations in the SMN1 gene on chromosome 5q.
The genetic defect leads to profound Survival Motor Neuron (SMN) protein deficiency, causing degeneration of alpha motor neurons in the anterior horn of the spinal cord, muscle atrophy, and respiratory failure.
Gene therapy aims to provide a definitive, functional replacement of the defective SMN1 gene, altering the disease's natural history from a uniformly fatal condition to a manageable chronic state.

Agent: Onasemnogene abeparvovec-xioi (Zolgensma) is a recombinant monogenic gene replacement therapy.
Vector Mechanism: Utilizes a non-replicating, self-complementary Adeno-Associated Virus Serotype 9 (AAV9) capsid, uniquely capable of crossing the blood-brain barrier via intravenous administration.
Episomal Persistence: The SMN1 transgene does not integrate into the host genome, eliminating insertional mutagenesis risk. It persists as an independent episome within the cell nucleus.
Sustained Expression: Because alpha motor neurons are post-mitotic, the episomal DNA is not diluted by cell division. A continuous hybrid CMV enhancer/chicken beta-actin promoter drives rapid, sustained production of full-length SMN protein.

Intravenous Formulation (Zolgensma): Approved for pediatric patients aged under 2 years with bi-allelic SMN1 mutations (applicable to symptomatic infants and pre-symptomatic neonates).
Intrathecal Formulation (Itvisma): FDA approved in November 2025 for patients $\geq$ 2 years, based on STEER Phase 3 trial data showing statistically significant motor function gains.
National Policy For Rare Diseases (NPRD) 2025: SMA is classified under Group 3 (high-cost lifelong therapy), providing up to ₹50 lakh per patient via Rashtriya Arogya Nidhi and Centres of Excellence.
IAP Guidelines (2025–2026): Endorses referral to Centres of Excellence for confirmed cases, prioritizing presymptomatic treatment and multidisciplinary follow-up.

Protocol Phase	Specific Clinical Requirements
AAV9 Antibody Titers	Measured via ELISA. Titers > 1:50 are an absolute contraindication (maternal/environmental antibodies will neutralize the vector and trigger severe immune responses).
Systemic Screening	Requires entirely normal liver function tests (ALT, AST, total bilirubin, PT/INR). Baseline platelet count, complete blood count, and troponin-I levels must be evaluated.
Administration Route	Delivered as a single-dose, slow intravenous infusion over 60 minutes.
Immune Modulation	Systemic prednisolone (1 mg/kg/day) must be initiated exactly 24 hours prior to infusion to suppress capsid immune response. Maintained for a minimum of 30 days post-infusion and tapered only if transaminases normalize.

Acute Hepatotoxicity: Triggered by an immune-mediated T-cell response against the AAV9 capsid causing acute hepatocellular injury. Mandates continuous liver function monitoring weekly for the first month.
Thrombotic Microangiopathy (TMA): Triad of microangiopathic hemolytic anemia, thrombocytopenia (sharp declines peak within two weeks post-infusion), and acute renal injury. Requires daily complete blood counts if suspected.
Cardiac Toxicity: Transitory elevations in cardiac Troponin-I reflecting potential localized myocardial inflammation.